SCHEMBL2902426

SCHEMBL2902426

COc1ccc(-n2c(=S)[nH]c3cc(C(=O)NCc4cccc(Cl)c4)ccc3c2=O)nc1OC

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ EGLN3 Q9H6Z9 4/20 0.60
▸ MEN1 O00255 5/20 0.56
▸ KMT2A Q03164 5/20 0.56
▸ USP2 O75604 2/20 0.56
▸ ALDH1A1 P00352 5/20 0.54
▸ MAPT P10636 4/20 0.54
▸ SMN1; SMN2 Q16637 2/20 0.52
▸ L3MBTL1 Q9Y468 1/20 0.52
▸ POLB P06746 2/20 0.51
▸ LMNA P02545 1/20 0.51
▸ RAB9A P51151 1/20 0.51
▸ TSHR P16473 1/20 0.50
▸ ROCK2 O75116 1/20 0.48
▸ ROCK1 Q13464 1/20 0.48
▸ TP53 P04637 3/20 0.48
▸ MITF O75030 1/20 0.48
▸ HPGD P15428 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2917295 0.93 MEN1 (0.56) EGLN3MEN1KMT2AUSP2ALDH1A1
SCHEMBL3134027 0.93 EGLN3 (0.65) EGLN3MEN1KMT2AUSP2ALDH1A1
SCHEMBL2894346 0.91 EGLN3 (0.72) EGLN3MEN1KMT2AUSP2ALDH1A1
SCHEMBL2917064 0.90 EGLN3 (0.58) EGLN3MEN1KMT2AUSP2ALDH1A1
SCHEMBL2894984 0.90 EGLN3 (0.59) EGLN3MEN1KMT2AUSP2ALDH1A1
SCHEMBL2901148 0.89 KMT2A (0.55) EGLN3MEN1KMT2AUSP2ALDH1A1
SCHEMBL2918091 0.89 EGLN3 (0.59) EGLN3MEN1KMT2AUSP2ALDH1A1
SCHEMBL2902571 0.89 EGLN3 (0.60) EGLN3MEN1KMT2AUSP2ALDH1A1
SCHEMBL2903007 0.89 EGLN3 (0.60) EGLN3MEN1KMT2AUSP2ALDH1A1
SCHEMBL2916904 0.88 EGLN3 (0.57) EGLN3MEN1KMT2AUSP2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298324-A1 Prolyl Hydroxylase Inhibitors SMITH KLINE BEECHAM CORPORATION (US) 2010-11-25 — — US claimed
EP-2240178-A1 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-10-20 — — EP claimed
WO-2009086044-A1 PROLYL HYDROXYLASE INHIBITORS SMITH KLINE BEECHAM CORPORATION (US) 2009-07-09 — — WO claimed
US-20100298324-A1 Prolyl Hydroxylase Inhibitors SMITH KLINE BEECHAM CORPORATION (US) 2010-11-25 — — US disclosed
US-20100298324-A1 Prolyl Hydroxylase Inhibitors SMITH KLINE BEECHAM CORPORATION (US) 2010-11-25 — — US disclosed
US-20100298324-A1 Prolyl Hydroxylase Inhibitors SMITH KLINE BEECHAM CORPORATION (US) 2010-11-25 — — US disclosed
WO-2009086044-A1 PROLYL HYDROXYLASE INHIBITORS SMITH KLINE BEECHAM CORPORATION (US) 2009-07-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298324-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 EGLN3 2/4885MEN1 4104/4885KMT2A 395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback